Hepaxane

Hepaxane is a prescription anticoagulant that contains the active ingredient enoxaparin sodium, a low‑molecular‑weight heparin, supplied as a sterile solution for subcutaneous injection (strength not specified). It is marketed in the European Union and belongs to the therapeutic class of anticoagulants. Hepaxane works by enhancing antithrombin III activity, which reduces the formation of blood clots in at‑risk patients. It is typically prescribed by physicians experienced in anticoagulation therapy.

Hepaxane is indicated for several clinical situations where anticoagulation is required.

- Prevention of deep vein thrombosis (DVT) in patients undergoing orthopedic surgery or who are immobilized. - Treatment of established DVT to reduce clot propagation. - Prevention and treatment of pulmonary embolism (PE). - Anticoagulation during haemodialysis to maintain circuit patency. - Prophylaxis of thromboembolic events in patients with acute medical illness at risk of clot formation. - Bridging anticoagulation for patients transitioning from oral anticoagulants to therapeutic levels of parenteral therapy.

The safety profile of Hepaxane reflects the pharmacology of low‑molecular‑weight heparins, with both frequent mild reactions and less common serious events.

Common: - Injection site erythema, pain, or bruising. - Minor gastrointestinal upset such as nausea. - Transient increase in activated partial thromboplastin time (aPTT) without clinical bleeding. - Mild headache or dizziness. - Mild local swelling at the injection site.

Serious: - Major bleeding, including intracranial or gastrointestinal hemorrhage. - Thrombocytopenia, particularly heparin‑induced thrombocytopenia (HIT). - Allergic reactions such as rash, urticaria, or anaphylaxis. - Elevated liver enzymes indicating hepatic injury. - Spontaneous spinal or epidural hematoma, especially after neuraxial procedures. These events are reported in clinical practice and should be monitored during therapy.

When prescribing Hepaxane, clinicians should evaluate patient‑specific factors and follow established safety measures to minimize risk.

- Assess renal function; dose adjustment may be required in severe impairment. - Review history of bleeding disorders or recent major surgery. - Monitor platelet counts regularly to detect heparin‑induced thrombocytopenia. - Use caution in patients with uncontrolled hypertension. - Avoid use in individuals with known hypersensitivity to enoxaparin or other heparins. - Consider pregnancy status; benefits must outweigh potential risks. - Evaluate concomitant use of other anticoagulants or antiplatelet agents.

Hepaxane may interact with other medicines that affect coagulation or platelet function, requiring dose adjustments or enhanced monitoring.

Avoid: - Concurrent use with other injectable or oral anticoagulants (e.g., warfarin, direct oral anticoagulants) unless specifically directed. - Combination with systemic thrombolytic agents (e.g., alteplase) due to heightened bleeding risk.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or aspirin, which can increase minor bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents that may impair platelet aggregation. - High‑dose corticosteroids, which may significantly potentiate anticoagulant effects. - Renal‑clearing drugs that could alter enoxaparin exposure (e.g., aminoglycosides).